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Abstract:  Bioproducts are often presented as one of the potential saviours of Canadian 
agriculture, offering non-food applications for agricultural products.  However, relatively little is 
known about the sector or the characteristics of the firms.  This paper presents an analysis of the 
Canadian bioproducts sector based on the first survey of bioproduct firms in Canada.  The survey 
was performed by Statistics Canada in 2004 using 2003 firm results. 
  
The paper analyzes the responses to the bioproducts survey on two important dimensions, by 
region and firm size.  The results indicate that for most of Canada’s 232 bioproducts firms, 
bioproducts are just one part of the business activities, accounting for less than one third of 
employees and slightly more than one quarter of total firm revenue. Bioproduct activities provide 
both market and environmental benefits.  The major challenges to the industry are financing and 
regulation.  However, the relative importance of bioproducts, benefits and strategies and the 
focus and success of firms vary dramatically by region and by firm size.  
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Canada, like many other countries, has been actively developing bioproducts and promoting the 
companies behind them.  Although bioproducts in some forms have been around for years, 
recently the production of bioproducts from agricultural biomass has gained considerable 
attention.  There is a perception that using agricultural biomass as an input will increase demand 
for agricultural commodities with positive impacts on commodity prices.  In the case of sugar cane 
there is evidence that this perception may be justified.   
 
This paper examines the state of the Canadian bioproducts industry through an analysis of the 
responses to a 2004 Statistics Canada survey on the industry.  For the purposes of the survey 
bioproducts were defined as those products which were derived from biomass, specifically 
biomass from agricultural crops, forestry, marine & aquaculture, food processing, animal manure, 
industrial and municipal organic waste. The analysis is presented on two dimensions, industry 
characteristics by province or region and by firm size.  In 2003, the bioproducts sector in Canada 
exhibited striking regional differences on some dimensions but similarities on others. The results 
will serve as a valuable input to managers and policy makers. 
 
Methods 
To better understand the Canadian bioproducts sector, Agriculture and Agri-Food Canada (AAFC) 
commissioned Statistics Canada to undertake the first national bioproducts survey in the world.   
The survey was based partially on the Biotechnology Use and Development Surveys administered 
by Statistics Canada every two years.  The Bioproducts Development Survey was administered in 
2004 with firms required to answer questions and report results based on their 2003 data. 
 
The data analyzed in this report was organized and reported on two dimensions.  The first is 
regional, with data provided for the Atlantic Provinces as a single region and for each of the 
remaining six provinces individually. The second categorization is by firm size, measured by the 
number of employees.  Firms are classified as small (less than 50 employees), medium (50-149 
employees) and large (more than 149 employees).  For this initial analysis, data was not provided 
on other dimensions or on the two dimensions simultaneously, and so the analysis necessarily is 
performed on these two dimensions.   
  2Results: Canadian Bioproducts Businesses 
 
Two hundred and thirty-two firms across Canada participated in the production or development of 
bioproducts during 2003.  Some of the most important characteristics of Canadian bioproduct 
firms are identified by region in Appendix 1 and by firm size in Appendix 2.  Seventy percent of 
Canada’s bioproduct companies were located in Quebec, Ontario, or British Columbia.  
Approximately 66 percent of firms were small in size, with less than 50 employees. Of the 
remaining firms 17.2 percent were medium sized with 50 – 149 employees, and 16.4 percent were 
large firms with more than 149 employees.    
Entry into the Bioproducts Sector 
 
Most of the firms surveyed had been in the business of bioproducts for a relatively short period of 
time.  Sixty-five percent had been involved in bioproduct-related activities for 10 years or less, 
and for small firms the percentage 10 years or less increased to 75 percent.  Quebec appeared to 
have created an environment conducive to entry into the bioproduct sector; forty-three percent of 
Quebec firms were five years old or less.  About thirty-nine percent of firms in Alberta and 
Saskatchewan were five years old or less compared to less than thirty-five percent of firms in all 
other regions.   The proportion of firms under five years of age was markedly higher for small 
firms (42.6 percent) compared to 17.4 percent and 17.8 percent for medium and large firms 
respectively.   
 
Approximately 19 percent of Canadian bioproducts firms originated as spin-offs.   Not 
surprisingly, most were small (86 percent) and none were large.   The vast majority originated 
from either universities (64 percent) or other firms (32 percent).  Quebec was home to nearly half 
of all spin-off companies, and 57 percent of all spin-offs from companies. Alberta and Ontario 
spin-offs were almost exclusively from universities. Government agencies did not figure 
prominently in bioproduct company spin-offs.  Although some firms began their involvement in 
bioproducts through collaborations with other firms/organizations (15 percent), most companies
  3(66 percent) entered the bioproducts field as the result of internal company research and 
development Figure 1.  The remaining firms entered through M&A activity, purchasing another 
firm’s activities, or other means. 














Region  #  %  #  #  #  # 
Canada 44   28  14  F  F 
Atlantic F   0  0  0  F 
Quebec 20  45.5  %  11  8 F  0 
Ontario 10  22.7%  9  1  0  0 
Manitoba 0    0  0  0  0 
Saskatchewan 3  6.8%  0  3  0  0 
Alberta 7  15.9%  7  0  0  0 
British 
Columbia F    0  F  0  0 
Note:  F indicates unreliable data not released by Statistics Canada 
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Figure 1: Initial entry the bioproducts sector, 2003 
 
Ownership 
More than 40 percent of bioproducts firms in Manitoba, Alberta and B.C. were public companies 
compared to less than 30 percent of those in other provinces (Appendix 1). At least 80 percent of 
firms in all regions are Canadian-owned, with the exception of Manitoba and Alberta where 67 
and 70 percent of firms were owned by Canadians.   
  4Large firms are far more likely to be public companies, and more likely to be foreign owned than 
smaller companies.   Only 18 percent of firms were subsidiaries of multi-national corporations 
(MNC’s); 44 percent of medium sized firms were in this category.  Predictably, larger firms were 
more likely to be public and foreign-owned.  
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(< 50)  154  19.8%  8.0  91.9 
Medium  
(50 – 149)  40 37.1%  44.0  74.1 
Large  
(>149) 38  60.1%  31.5  60.3 
 
Bioproduct Development 
Canadian firms were actively developing and producing a variety of bioproducts.  In 2003, the 232 
firms had a total of 1,048 products under development or in production, an average of  4.5 
products/firm.  Of these, 60 percent were already on the market, 18 percent were mid-
development, and 22 percent were in early stages.  The largest category of products by far was 
bio-chemicals, which made up 41 percent of all bioproducts under development or on the market   
  5We can see that the distribution of products also varies by firm size (Figure 2) 
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Figure 2: Bioproduct development by product type, 2003  
 
Product development patterns were fairly consistent across all product types with small firms 
having the largest number of products under development.  The exception is in bio-fuels/bio-
energy products where large companies dominate.  Large firms were also very involved in bio-
chemicals.  This result reflects the nature of the chemical and energy businesses, which are 
dominated by large companies with significant resources.  
 
It is interesting to note that the bioproducts sector saw more products on the market than in 
development, especially from medium and large firms (Figure 3).  Small companies were more 
focused on the early stages of research and development than larger firms but still had many 
products on the market.  This is typical, as much of the research and development and proof of 
concept work for the development process is done in small firms.  Medium sized and large 
companies have the resources to produce and market a limited number of commercial products so 
they tend to dominate the last stage of development.   
 



























Agricultural crop and forestry biomass were the most common forms of biomass used in 2003 
(Appendices 1 and 2).  These sources were used by 93 and 77 firms, respectively, more than twice 
the number of firms using any other single type of biomass.  (Note that responses are not mutually 
exclusive.)  Agricultural crop biomass was the dominant form used in both small and medium 
sized firms, while large firms most often used forestry biomass in their production. Infrequent use 
was made of marine products, food processing products, animal manure, or municipal organic 
waste.   
 
Only 18 percent of all Canadian firms had their biomass on site, and nearly 60 percent of firms 
were farther than 50 km from their primary source.  This suggests that an active market with 
substantial search and transport costs exists in the sourcing of biomass inputs.  Off-site sourcing 
was especially important for small and medium sized firms (Figure 4); as firm size increases, the 
share of biomass input sourced on-site increases, a finding consistent with the increasing level of 
by-product used with increasing firm size.  This would suggest that smaller firms were focused 
more on processing biomass not produced by the firm, while large firms used biomass processing 
as a means to develop a revenue generating output based on some other production process.  
Alternatively, larger firms may be adjacent to sources of their biomass inputs, thus taking 
advantage of agglomeration economies. 
   
  7Percentage of firms by distance from principal source of 
biomass, by firm size
 
Figure 4: Percent of firms by distance from location of principal biomass input, by firm size, 
2003 
 
Within Canada as a whole, most firms (65 percent) indicated they sold their bioproducts directly 
to consumers or distributors, followed by 47 percent who reported sale to another firm for use as 
an intermediate input and 33 percent who use their bioproduct internally.  Note that the responses 
to this question were not mutually exclusive and that the responses varied by firm size (Table 3) 
Table 3: Percent of firms by end user of bioproducts, by firm size, 2003 
 
Firm Size 
Sold directly to  
consumers or 
distributors 
Sold to other firms 
to be used as 
input(s) 
Produced for  
internal use 
Small (less than 50 employees)  63.9%  43.0%  26.9% 
Medium (50 - 149 employees)  78.2%  70.9%  22.0% 




For most firms bioproducts was only part of their business.  Of nearly $12 billion in revenue 
generated by Canadian bioproducts firms in 2003, only 26 percent was derived from bioproduct 
activities (Appendix 1).  With the exception of Saskatchewan and Alberta, firms in most provinces 
obtained more than 30 percent of their revenues from bioproduct activities.  Ontario had the 
highest total provincial revenue from bioproducts at $871 million, but firms in Quebec, Alberta 
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  8activities.  Bioproduct revenues were highly dependent on exporting, with Alberta and 
Saskatchewan firms generating 81 and 78 percent respectively of their total bioproduct revenues 
from exports (Appendix 1).   
 
Bioproduct revenues as a percentage of total revenue also varied widely depending on firm size 
(Appendix 2).  Medium sized firms derived the largest portion of total revenue and exports from 
bioproducts.  Large firms appear to incorporate bioproducts as just one line of business; only 18 
percent of total revenue was derived from bioproducts. 
 
Bioproduct Research and Development Expenditures 
 
Canadian firms each spent an average of just over $1 million on R&D in 2003, with 39 percent 
(approximately $400,000) devoted to their bioproduct programs (Appendix 1).  Firms in Alberta, 
Manitoba, and Quebec spent more than the average on both total R&D and bioproduct R&D.  
Quebec firms spent $1.3 million and $571,543 on average total and bioproduct R&D respectively, 
nearly twice as much as Ontario firms.  Although their total spending was lower, Ontario firms did 
utilize 46 percent of their R&D spending to fund bioproduct development, which was the highest 
of any region.  Quebec firms were a close second with 43 percent.   
 
As a percentage of total R&D, small firms were the most intensely focused on bioproduct 
development, with seventy-two percent of R&D expenditures aimed at bioproducts (Table 4).  
Large firms focused roughly a fifth of their R&D budgets on bioproducts R&D, spending only 
marginally more in total than medium sized firms and almost double what small firms spent.  
 









Average Total R&D 
Small $444,369  $321,395  72% 
Medium $1,516,962  $512,147  34% 
Large $2,906,076  $618,863  21% 
 
  9Intellectual Property 
 
Thirty percent of all Canadian firms either possessed or had applied for some form of Intellectual 
Property (IP) rights during 2003.  Most obtained their IP through either a patent assignment or a 
licensing agreement.  Quebec firms were the most likely to have acquired or pursued IP protection 
for their technology (43 percent of firms), compared with 30 percent of B.C. firms and just 23 
percent of Ontario firms (Appendix 1).  Quebec was the only province where firms viewed IP 
audits as one of their most important knowledge management strategies. With the exceptions of 
Ontario and Quebec, the percentage of firms which possessed/pursued IP rights during the year 
was fairly stable across the country, ranging from 28 percent to 32 percent of firms.  
 
Ontario firms were the most likely to have obtained foreign IP as a percentage of all IP (Figure 5) 
while firms in Alberta and Quebec were least likely.  All of Manitoba’s IP came from foreign 
sources but the data on both Manitoba and Saskatchewan data are insufficient to make significant 
conclusions. 
Number of firms with IP and the origin of the IP, by region, 2003 
 
Figure 5:  Number of firms which acquired by source of IP, by region, 2003 
 
Small firms were also most likely to have acquired/pursued IP protection, with 36 percent having 
done so (Appendix 2).  This is also consistent with other areas of the survey, which indicate that 
the small firms may be more involved in the early development of new technologies.  Medium and 
large sized firms had relatively lower rates, at 15 percent and 25 percent respectively.    The 
proportion of firms which obtained IP from domestic sources varied from 50 percent for medium 
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  10Contracts and Collaborations 
 
Canadian firms relied heavily on outside organizations for research and development activities, to 
reduce costs and risk exposure and to access new markets.  These relationships were important 
knowledge management strategies for bioproducts firms who accessed skills and capabilities in 
other organizations either through contracts or collaborations.   
Contracts 
 
Canadian companies spent nearly $117 million on bioproduct-related contracts in 2003.  On 
average, 36 percent of firms contracted out some part of their bioproduct activity during the year, a 
percentage that was fairly stable across firm sizes, but varied by province (Table 5).  Forty eight 
percent of Manitoba firms were involved in contracting, while Ontario firms were the least 
involved in this type of arrangement.  A total of $76.4 million of contracts were provided by 
Alberta companies, while another $16.4 million came from Quebec firms, together representing 80 
percent of the total value of contract expenditures by Canadian bioproducts firms.  Most 
bioproduct-related contracts were with private research labs and universities.  Contracts with these 
institutions comprised 40 percent and 37 percent, respectively, of all contracts (Figure 6).   
Table 5: Total number of contracts, by partner type and region, 2003 
 
Type of Partner 
Region 
Percentage of 
Firms Involved in 
Contracts 
Private 




firm  Other 
Canada  35.5%  114 108  21  23  23 
Atlantic  29%  0 F  0  F  4 
Quebec   38.6%  50 39  12  7  9 
Ontario   24.2%  10 17  3  F  0 
Manitoba   48.3%  15 5  0  7  0 
Saskatchewan  45%  9 4  3  0  8 




16 25  3  3  0 
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Figure 6:  Contracting arrangements by partner type, 2003 
 
 
Analysis of contracts by partner by firm size reveals the extent to which small firms rely on 
contracts. While only 36% of small firms were involved in contracts they contributed 70% of total 
contract value.  Small firms tended to have more contracts with private labs than with universities, 




Collaborations were an important source of knowledge and expertise for Canadian bioproducts 
firms.  Thirty-five percent were involved in collaborations with other organizations in 2003.  
Fifty-one percent of firms reporting collaborations cited the access to external scientific expertise 
as their primary motivation.  This appeared relatively common across all sizes and regions.  Cost 
reduction related to R&D activities was the second motivating factor.    As with contracts, firms in 
Ontario were least likely to be involved in collaborations (Appendix 1). Saskatchewan firms were 
most likely (at 58 percent) followed by Quebec firms (at 41 percent).   
 
Small firms were more likely than larger firms to be involved in collaborative arrangements 
(Appendix 2).  Their motivations were primarily to access external skills not available inside the 
organization.  Small firms were more likely to work with private sector organizations, while larger 
firms collaborated more closely with academic institutions, for both access to expertise and 
reducing the cost of R&D. 
 
  12Foreign Collaborations 
Foreign collaborations were relatively rare. Only 22 percent of bioproducts firms in Canada had 
entered into foreign collaborations.  Due to confidentiality reasons the only available data is for 
Quebec, Ontario, Saskatchewan and B.C. who have 18, 9, 7, and 7 collaborations with foreign 
partners, respectively.  Saskatchewan had the most firms involved, at 38 percent, and Ontario the 
fewest (of the numbers given) at 16 percent.  Data is reported for small and large firms only.  Only 
23 percent of small firms had foreign collaborations, compared to 25 percent of large firms. The 




Of the 232 respondents from across Canada, 54 percent attempted to raise capital in 2003 to assist 
in the development or production of bioproducts (Table 6).  Most firms were at least partially 
successful. A total of over $275 million was raised by the 96 successful companies. However, 
funding success varied widely from province to province.  Alberta firms raised nearly $93 million 
with an average of $7 million per firm seeking capital, ten times the Ontario average.  Quebec had 
a high number of firms seeking capital, a success rate of 86 percent and Quebec firms secured over 
half of the capital raised in Canada.  Firms in Atlantic Canada, Ontario and Saskatchewan 
appeared to have difficulty securing funding.  
 






















Canada   232  124  53.6%  96  77.4%  275,072  2,218 
Atlantic 15  6  39.2%  4  66.7%  F  407 
Quebec   72  44  61.4%  38 86.4%  126,022  2,864 
Ontario    53  28 53.2% 16  57.1% 19,601  700 
Manitoba    9 3  34.8%  3  100.0%  F 2,351 
Sask.   18  9  49.9%  8  88.9%  1,586  176 
Alberta    27  13 47.9% 11  84.6% 92,732 7,133 
British Columbia   38  21  55.0% 15  71.4% 25,636 1,221 
 
Examining financing by firm size reveals some interesting anomalies.  Small firms were most 
likely to seek financing, least likely to succeed but those that were successful raised the most on 
  13average (Table 7).  Interestingly, funding for large firms was typically much lower than for small 
or medium sized firms and they achieved far less of their target funding (Figure 7).   
Table 7: Financing Success, by firm size, 2003 
 
  








Firm Size  Number    Percent  Number  Percent  ($000)  ($000) 
Small  93 60.4% 70 75.3%  $211,817  $1,362 
Medium  18 45.0% 15 83.3% $45,717  $1,149 
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Figure 7:  Firm financing success, by firm size, 2003 
 
The number one reason cited by firms of all sizes for pursuing financing was to fund R&D.  
Raising funds to repay investors and fund regulatory expenses was only important to small firms 
(likely due to firm structure and relative “newness” to the sector).  Medium and large firms 
required more funding for production and manufacturing since they were more focused on 
products on the market.  Just over half of firms, regardless of size, cited the need for operating 
capital as a financing objective. 
 
The funding received by these firms came from numerous sources.  Government programs 
comprised 43 percent of all sources of funding for Canadian firms.  Other common sources 
included Canadian based venture capitalists (13 percent) and angel investors/ family (15 percent).  
Less frequently used were financial institutions, public offerings, private placements, and 
alliances/ collaborations.  Quebec companies captured most of the funding and led in obtaining 
  14funding from most public and private sources (Figure 8).   Loan programs were often administered 
provincially.  Alberta firms had a disproportionately high number of the private placements, which 
might account for their very high levels of funding per firm relative to companies in other 
provinces. 
 
















































Figure 8:  Number of firms using different financing methods, by region, 2003 
 
Various reasons were cited for the firms’ inability to access capital funding more successfully,  the 
most common being the lack of availability of capital.  The other major reasons cited pertained to 
the development stage of the product/technology (too early) or a lack of proven market demand, 
however, these applied mostly to small-sized firms who tended to have early-stage products.   
There was little regional variation in the reasons.  
 
Use of Government Support Program  
 
Participation in government support programs was only moderate with approximately one third of 
firms applying to federal programs and one third applying to provincial programs (Table 33).  
With the exception of Quebec, applications to federal programs were above those of provincial 
programs.  In Quebec, participation in provincial programs was 70 percent, more than double the 
national average (Table 8). 
 
 






By Region  %  % 
Canada   33.1  34.8 
Atlantic 41.9  29.1 
Quebec   38.9  70.4 
Ontario   15.6  8.1 
Manitoba   59.3  F 
Saskatchewan   50.5  46.0 
Alberta   38.0  16.5 
British Columbia   25.2  18.6 
 
Small firms made more use of both federal and provincial support programs (at approximately 42 
percent for each category) than larger firms (24 percent each). Medium firms presented an 
interesting anomaly, making relatively little use of either category of support programs but using 
provincial programs (18 percent) more frequently than federal programs (11 percent).  Technology 
development programs were most likely to be accessed but small firms also made extensive use of 
loan guarantees, information and training programs.  Medium and large firms accessed technology 
development and training primarily.  Both small and medium sized firms used provincial training 
programs more than federal programs. 
 
Use of funding under the Scientific Research and Experimental Development (SR&ED) tax 
program varied widely among the provinces and firm sizes (Table 9).  Firms in Manitoba and 
Quebec were much more likely to use the program but Manitoba and B.C. firms were far ahead in 
terms of the amount requested by participating firms.  Alberta was third, with all other regions 
trailing. 
 

















By Region  #  %  $'000  $'000  $'000 
Canada   90  47.4%  87,198  792  1,299 
Atlantic 4  26.7%  F  F  3,761 
Quebec   38  65.3%  28,813  613  1,173 
Ontario   15  37.7%  5,500  275  840 
Manitoba   6  55.6%  15,873  3,175  1,071 
Saskatchewan   5  38.9%  X  x  315 
  16Alberta   7  25.9%  11,481  1,640  3,891 
British Columbia   14  52.6%  21,970  3,139  882 
 
Small firms were more likely to use of the SR&ED tax credit program but they applied for and 
received less than larger firms (Table 10).  Large size firms have been the most successful in 
securing tax credits over the last five years.  















credits/firm in region 
Firm Size  #  %  $'000  $'000  $'000 
Small 77  50.0%  21,792  283  795 
Medium 19  47.5%  26,079 1,373  2,321 




It is estimated that 24,195 people were employed by firms engaged in the development and/or 
production of bioproducts in Canada in 2003.  Of these, the greatest proportion was in Quebec, 
followed by Ontario, the Atlantic Provinces and British Columbia.  Around 75 percent were 
employed in large firms, with only 9 percent employed in small firms, indicating that, even though 
two thirds of the firms are small, large firms dominate the sector in terms of number of employees. 
 
Within the firms, an estimated 7,864 of employees had responsibilities related to bioproducts.  
Around 32 percent of employees were involved in bioproduct activities including scientific 
research and development (1,022), technicians (1,007) and management, marketing, finance and 
production (5,606), with the remainder (229) engaged in a variety of other related tasks.  Over 58 
percent of employees with responsibilities related to the development and/or production of 
bioproducts in Canada were employed by companies in Quebec or Ontario.  More than 38 percent 
of all scientific research and development personnel were employed in Quebec, with a further 22 
percent in Ontario and 15 percent in British Columbia.  The Atlantic Provinces account for almost 
8 percent of scientific research and development personnel but only 3 percent of total employment 
in the sector. 
 
The focus of small firms on early stage R&D was evident in employment patterns. Small firms 
accounted for 43 percent of all employees engaged in scientific research and development across 
the bioproducts sector, but only 15 percent of those involved in management, marketing, finance 
  17and/or production. On an individual firm basis small firms committed half of their personnel to 
development (Table 11). By contrast, large firms accounted for 51 percent of management, 
marketing, finance and/or production personnel but only 29 percent of employees engaged in 
scientific research and development.   
 





R&D  Technicians 
Management/marketing/ 
finance/production  Other  Total 
Small 2.85  2.56  5.43 0.31  11.14 
Medium 7.33  9.2 47.7  4.58  68.78 
Large 7.63  6.42  75.32  0  89.4 
 
 
Benefits from Bioproduct Development and Production 
 
Respondents were asked to rate the importance of various benefits obtained by their firms as a 
result of bioproduct development or production.  The importance of each benefit was rated using a 
five point likert scale, where a low importance rating was scored as one and a high importance 
score was rated as a five.  A weighted average of the scaled responses was calculated, with the 
proportion of respondents selecting the various rating serving as weight.  This weighted average 
provided the importance score used to rank the various benefits. 
 
For all firms in Canada, increased sales/market share were ranked as the most important, followed 
by development of new market niches/new products, reduced damage to the environment, 
improved product value/performance, increased product range, reduced production cost and finally 
reduced energy consumption.  Across regions, either increased sales/market share, development of 
new market niches/new products or reduced damages to the environment was the top ranked 
benefit (based on the importance score).  Moreover, these benefits are generally in the top three 
ranked benefits within each region.  Exceptions do exist to this general conclusion.  For instance, 
in all but Atlantic Canada, and Saskatchewan, improved product value/performance ranked higher 
than either increased sales/market share, reduced demand to the environment or development of 
new market niches/new products.  Reduced production cost and reduced energy consumption were 
viewed as less important.  On a regional basis, however, firms in the Atlantic region, Manitoba, 
  18and B.C. ranked reduced production cost and reduced energy consumption higher than other 
benefits.  
 
Responses based firm size (Table 12) indicate that small firms viewed developing sales, new 
markets and improving the value or performance of their products as the most important 
bioproduct benefits.  This was very similar for medium size firms except that reduced 
environmental impact replaced new market development.  Improved product value or performance 
had the highest importance score for medium firms. The importance of environmental impact 
appears to increase with firm size since large firms ranked reduced damage to the environment as 
the most important. 
 
The benefit rankings are not entirely unexpected.  One might expect smaller firms to be seeking 
market expansion opportunities as a means to facilitate growth and sustainability.  Medium size 
firms, who might already have well developed product lines and markets, might well focus on 
generating additional value (or performance) with existing products.  Larger firms may view 
reduced environmental damage as very important as this lessens the negative publicity they 
receive and mitigates any liability they may face arising from environmental damage.  They are 
also actively involved in using by-products. Reduced production cost and energy consumption had 
higher importance scores for larger firms than for small and medium firms suggesting that they are 
more focused on cost control than market growth.  Such differences in business strategy, based on 
firm size, are not unexpected. 


























Small 3.12  2.58  3.76  4.22  3.78  3.87 4.12 
Medium 3.27  2.52  3.55  3.07 3.13 3.63 3.59 
Large  3.91 3.71  4.36  3.23 2.79 2.93  3.48 
 
Note: The three highest ranked benefits for each firm size are identified by bold text. 
 
Barriers to Bioproduct Development and Production 
Respondents were asked to rate the importance of various barriers their firm experienced in the 
development or production of bioproducts.  As with the benefits question, the rating of each 
  19benefit was scaled using a five point likert scale and the responses were used to develop 
importance scores for each barrier by region and firm size.  The two major barriers by region and 
firm size are shown in (Appendices 1 and 2).  For bioproduct firms in Canada, lack of financial 
capital, high cost and timeliness of regulatory approval and higher price of raw materials or 
feedstock were the top three barriers, based on the importance scores.  In Quebec, Manitoba and 
B.C. unreliable supply of raw material or feedstock also rated in the top three importance scores.  
In Manitoba, the most important barrier was higher transport cost of main feedstock or raw 
material.   
 
The higher cost and timeliness of regulatory approval was perceived as one of the top three 
barriers to bioproduct development by bioproduct firms in Canada, regardless of their size. For 
small firms the other two most important barriers were lack of financial capital and lack of 
adequate product standard or certification.  The importance of these barriers is not unexpected.  
Small firms often encounter difficulties sourcing capital from various sources.  The importance of 
lack of adequate product standard or certificate may reflect the fact that smaller firms may have 
truly novel innovations for which appropriate standards do not exist.  In conjunction with the 
regulatory approval process issues, it would seem that smaller firms not only need additional 
capital, but also a clear, more flexible regulatory/standards approval process.   
 
For medium sized firms, the other important barriers were the high cost of raw material or 
feedstock and lack of technology or technical information.  The latter barrier is somewhat 
surprising as one would expect this group of firms to be more mature than smaller firms and have 
adequate access to technology and information.  Besides regulatory approval costs, important 
barriers for large firms were higher transportation cost of main feedstock or raw material and 
higher price of raw materials or feedstock.   
 
It would thus seem important to develop human capital that enables firms to navigate their way 
through the regulatory system.  Alternatively, the regulatory system needs to be modified to make 
it easier for firms to take a concept from R&D to the market. 
Business Strategies 
 
Respondents to the survey were presented with a series of strategies related to knowledge 
development and their overall business and asked to indicate how important each had been for 
  20their firm in 2003 on a five-point scale from “low” (1) to “high” (5).  Across the sample as a 
whole, the most important strategies related to acquisition of knowledge from other industry 
sources (including industry associations, competitors, clients and suppliers) and the 
commencement of new research and development projects (Table 13).  Entering product trials 
and/or adapting products for increased market penetration were also important to companies 
within the sector.   Changes in firm size through downsizing or acquisitions, mergers or joint-
ventures were relatively unimportant strategies. 
 
Table 13: Mean importance of strategies for firm, 2003 
 
Strategy  Mean 
Importance 
Score 
Acquired and used knowledge obtained from other industry sources 
such as industry associations, competitors, clients and suppliers 
3.3 
Began new research and development project  3.2 
Entered product trials/adapted products or processes for increased 
market penetration  
3.2 
Developed/encouraged staff education/upgrading  3.1 
Acquired and used knowledge obtained from public research institutions 
including universities and government laboratories  
3.0 
Developed firm policies and practices for knowledge/intellectual 
property protection 
2.8 
Expanded into foreign markets  
 
2.7 
Used and updated databases of scientific information   2.6 
Conducted an intellectual property audit to ensure protection of products 
and processes at all stages of development 
2.4 
Downsized operations of the firm  
 
1.9 
Increased firm size through acquisition, merger or joint venture   1.8 
 
Broadly, across the provinces these same knowledge development and business strategies 
remained important for bioproduct firms.  However, there were some notable differences.  In 
Quebec, the Atlantic Provinces and Saskatchewan knowledge acquisition through public 
institutions, including universities and government laboratories, were relatively more important 
strategies for knowledge development. As discussed earlier, Quebec is the only province which 
considers IP audits a fairly important business strategy.  
 
  21Across respondents by company size, new R&D projects and product trials emerged as most 
important business strategies.  Knowledge development strategies overall, and acquisition and use 
of knowledge from public research institutions in particular, were of much less importance for 
medium-sized firms than either smaller or larger companies.   
 
Common Themes in the Canadian Bioproducts Sector, 2003 
Bioproducts are just one part of firm business activities and the proportion decreases with firm 
size - In general, bioproducts were a small part of the business activities for most of the 232 
Canadian firms involved in bioproducts in 2003.  Firms had less than one third of their employees 
involved in bioproducts and derived just over one quarter of their revenue from bioproducts 
activities.  Almost half of firms secured inputs from by-products.  This provides the industry with 
greater stability and certainly of income than if they were focused entirely on bioproducts 
development. 
 
Bioproduct firms generally entered the business as a result of internal R&D - Nearly two thirds 
of firms entered the bioproducts business primarily as a result of internal research and 
development.  The most common benefits from bioproduct involvement pertained to new 
product/market opportunities, but firms also secured benefits relating to environmental impact and 
product performance. While reducing energy usage was a low-rated benefit, rising energy costs 
should increase interest in the development of bio-energy products. Thus, there are many reasons 
for firms to enter the bioproducts business and no obvious single motivation which can be used to 
promote the industry in general. 
 
Barriers to expansion include capital, particularly for small firms, and regulation – 
 The factors limiting the expansion of bioproduct activities are relatively consistent, with capital as 
the most commonly cited barrier and difficulties related to regulatory approval second.  Access to 
capital is the major barrier for small firms, but is less important for large ones.  Interestingly, less 
than half of survey respondents made use of the SR&ED Tax Credit program.   Cost and 
timeliness of regulatory approval was also among the top three barriers for all firm sizes and most 
provinces.  The related issue of lack of product standards or certification was relatively important 
across Canada and for small and large firms.  Also of interest are the factors not cited as barriers - 
  22problems related to intellectual property, human resources and negative public perception were not 
often rated as major problems. 
 
Knowledge Acquisition was and Important Strategy 
The final area of similarity across firms and provinces related to firm strategies.  Acquiring 
industry knowledge was rated as the top knowledge management strategy across all firm sizes and 
six of the seven regions.  Firms used a combination of internal and external knowledge 
management strategies, accessing external knowledge from industry and research institutions 
while at the same time promoting employee development.  Both contracts and collaborations were 
employed to facilitate access to external expertise and capabilities. 
 
Policy Implications:  
The different strategies and challenges of firms from different size and regions necessitates 
distinct policies to promote bioproduct development among Canadian companies.  
However, the common themes point out some reasonable starting points at the national level. 
 
The regulatory approval process was a challenge to firms across regional and size categories.  It is 
worthwhile investigating why this issue was raised so regularly and what can be done to improve 
the situation.  Further analysis is required to determine whether the issue is the same across all 
product categories.  
 
Addressing challenges related to lack of capital is a different matter since is particularly an issue 
for small firms operating in an area of relatively new technology.  While individual programs may 
be targeted at the bioproducts sector, programs aimed at promoting new technologies in general 
may help to create an environment conducive to the creation of new companies in a variety of 
technology sectors.  The relatively limited use of the Scientific Research and Experimental 
Development, particularly in some provinces, represents and opportunity to improve the flow of 
capital to support research.  Just under half of firms used the SR&ED tax credit program and only 
one third accessed federal and provincial support programs.  Identifying the reasons why firms do 
not apply or are not successful can improve program use and value to the industry. 
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One obvious conclusion is that different approaches are required depending on whether the target 
is promotion of bioproducts development in large firms or increasing the number and success of 
small bioproducts firms focused on developing new bioproducts. Large firms incorporate 
bioproducts into their existing businesses for environmental, cost and market reasons and would 
respond to incentives to further activities aligned with current business activities.  Small firms 
build a major portion of their business on bioproducts and commit a significant percentage of their 
scientific development resources to those products.  They tend to require assistance in every area 
from technology development to loan guarantees and training since a lack of both financial and 
personnel resources are significant factors limiting their development.  All categories have made 
use of training and those programs could be expanded in the future. 
 
Recommendations for Further Analysis 
 
This first analysis of the Canadian bioproducts sector provides a reasonable overview of the sector 
but was not intended to delve more deeply into the workings of the sector and the factors 
contributing to success in bioproduct development and commercialization. The analysis contained 
here was conducted based on regional or firm size differences.  In this regard, scope exists to 
develop cross-tabulations that interact, not only the regional and firm size variables, but also other 
variables such as firm age, nature of business arrangements, the impact of collaborations, etc.  At 
the same time, use of multivariate or other statistical methods can be used to test and measure the 
relationship between bioproduct development or business success and various firm specific 
factors.   
 
The bioproducts survey also presents an opportunity to create a baseline assessment of the sector 
and the firms.  Future studies will facilitate analysis of the evolution of the sector but also of 
individual firms common to this and future surveys.  Firm level longitudinal analysis will provide 
extremely useful information about the nature of firm bioproduct development and the role of 
different strategies and policy in shaping that development.  Given that this sector is predicted to 
grow at a significant rate over the next few decades, building an understanding of the sector and 
critical success factors as early as possible is essential.  25
   
Appendix 1:  Key Bioproduct Firm Indicators by Region (2003)    Note:  F indicates unreliable data. 
            Category  Canada Atlantic Quebec Ontario Manitoba Sask. Alberta B.C.
Number of Firms  232 15  72  53  9  18  27  38 
Firm Characteristics 
% < 5 years in BP 
% Public companies 
Avg. # of emp./BP emp. 







































100 / 39 
39.4% 
Entry into bioproducts 


















Top 3 Biomass Sources 
:% primary/ % by-prod. 
 
Ag/F/Other 
46 / 47 
 
F/Ag/Food 
61 / 22 
 
Ag/F/Marine 
46 / 47 
 
Ag/F/Other 
43 / 52 
 
Ag mainly 
50 / 45 
 
Ag/Manure/F 
47 / 53 
 
Ag/F/Other 
58 / 43 
 
F/Ag/Food 
37 / 51 
Revenue ($ 000): 
Average total/firm 
Average % from BP 

































R & D ($ 000): 
Average R&D/firm 
Average BP R&D/firm  
Avg. # of BPs under 
development/firm  
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IP -  % firms with IP   30.5%                28.5% 43.0% 23.0% 32.9% F 27.9% 30.2%
Collaborations  
-  % with collaborations 


























-  Top knowledge dev. 

























Benefits – Top two 
identified (PM = 
Product/Market) 
↑ Sales/ 




New PM/ ↑ 
Sales 




New PM/ Env. 
Impact 
New PM/ ↑ 
Sales 
Env. Impact/ 
↓ Prod’n cost 





















 Appendiz 2: Key Bioproduct Firm Indicators by Firm Size (2003) 
 
 Firm  Size 
Category Small  Medium  Large 
Number of Firms  154 40  38 
Firm Characteristics 
% less than 5 years in bioproducts 
% Public companies 
# of employees/ # BP employees 














476 / 89 
18.8% 
Entry into bioproducts 








Top Three Biomass Sources
2
Source:% primary/ % by-product 
 
Ag/F/Other 
48% / 46% 
 
Ag/F/Marine 
44% / 48% 
 
F/Ind/Ag 
40% / 53% 
Revenue ($ 000) : 
Average total/firm 
Average % revenue from BP 













Research and Development ($000): 
Average R&D/firm 










Average # of BP under 








-  % seeking financing 



















-  % with collaborations 











-  Top knowledge development 
-  Top business strategy 
Acquire Ind. Know. 
New R&D 
Acquire Ind. Know. 
Trials 
Acquire Ind. Know. 
New R&D 
Benefits – Top two identified  New PM/ ↑ Sales  Improve Value 
performance/↑ Sales 
Env. Impact/ ↓ 
Prod’n costs 






Price of Material/ 
Transportation 
                                                 
2 Ag: Agriculture, F: Forestry, Ind – Industrial Organic Waste 